Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today we ponder the vast open spaces of Boston’s unused life sciences labs, see a new biopharma IPO in the works, and expect a label expansion for some CAR-T blood cancer therapies.
The need-to-know this morning
- Bluebird Bio, in the early stages of a commercial launch of a gene therapy for sickle cell disease, raised up to $175 million in debt financing with Hercules Capital.
Boston’s empty life sciences labs
As the pandemic took off, real estate developers went into overdrive building life-science laboratories across Boston. While most office work was at a standstill, companies like Moderna were expanding and needed more and more space. Billions of dollars poured in to support the feverish demand. But now, as these buildings near completion, most will be empty.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect